Introduction {#sec1}
============

Controlled intraoperative cardiac arrest is indispensable in the majority of pediatric cardiac surgery procedures. One of the most important myocardial protection techniques is cardioplegia -- indirect or direct administration of cardioplegic solution to the coronary arteries. Both crystalloid cardioplegia and blood cardioplegia are widely used in pediatric cardiac surgery \[[@cit0001]--[@cit0003]\]. The choice of cardioplegic solution depends on the surgeon's preference or on the local institutional policy \[[@cit0004]\].

The advantages of crystalloid cardioplegia are the following: relatively low price, simplicity of use and myocardial protection up to 2 h after a single dose \[[@cit0001], [@cit0005]\]. Potential advantages of blood cardioplegia include: oxygen transfer by the red blood cells to the myocardium, free radical scavenging properties and physiologic osmotic pressure that protects against myocardial edema \[[@cit0001], [@cit0006]\].

The experience of many units shows clinical advantages of blood cardioplegia administration. However, the previous studies did not give an unequivocal answer as to which cardioplegic solution is the most beneficial (for all congenital cardiac malformations and all age groups of patients).

Aim {#sec2}
===

The aim of this study was to assess the impact of blood cardioplegia on postoperative clinical variables, in comparison with two types of cold crystalloid cardioplegic solutions, during open heart surgery in children.

Material and methods {#sec3}
====================

Patients {#sec3.1}
--------

One thousand one hundred and twenty-nine consecutive patients underwent surgical correction of different congenital heart diseases (CHD) with the use of cardiopulmonary bypass and cardioplegic solution administration in the Department of Pediatric Cardiac Surgery, Poznan University of Medical Sciences, between 2006 and 2012.

Medical records (surgical reports, case histories, local medical database and local data from National Cardiac Surgery Registry -- "KROK") were reviewed.

The most common cardiac malformations operated on during this period are presented in [Table I](#t0001){ref-type="table"} Demographic data according to the type of used cardioplegic solution are presented in [Table II](#t0002){ref-type="table"}.

###### 

List of operated cardiac malformations during 2006--2012

  Cardiac disease   Number of patients (% of occurrence)
  ----------------- --------------------------------------
  ASD II            260 (23)
  VSD               230 (20)
  AVSD              148 (13.1)
  ToF               111 (9.8)
  TGA               81 (7.2)
  AS/AI             81 (7.2)
  UVH               58 (5.1)
  AVVI              46 (4.1)
  TAPVR             20 (1.8)
  MIX               94 (8.7)

ASD II -- atrial septal defect, VSD -- ventricular septal defect, AVSD -- atrioventricular septal defect, ToF -- tetralogy of Fallot, TGA -- all spectrum of transposition of great arteries, AS/AI -- aortic valve malformations (complex and simple), UVH -- all spectrum of single ventricle disease, including hypoplastic left heart syndrome, AVVI -- isolated atrioventricular valve malformations, TAPVR -- all spectrum of total anomalous pulmonary venous return, MIX -- other, less frequent cardiac malformations.

###### 

Demographic data according to type of used cardioplegic solution

  Parameter                       FR                  ST                  BL
  ------------------------------- ------------------- ------------------- -------------------
  Demographic variables:                                                  
  * N*                            432                 440                 257
   Gender (female/male)           204/228             207/233             103/154
   Age \[days\]                   295 (77--741)       313 (82--967)       366 (116--999)
   Body weight \[kg\]             7.2 (4.1--11.5)     7.5 (4.1--13)       8.6 (4.9--13.5)
   Body surface area \[m^2^\]     0.37 (0.25--0.52)   0.38 (0.24--0.57)   0.41 (0.28--0.59)
   Down's syndrome                53                  49                  31
  Intraoperative variables:                                               
   CBP \[min\]                    83 (52--123)        89 (60--126)        81 (50--118)
   Ao-x-clamp \[min\]             42 (24--66)         45 (27--62)         43 (24--61)
  Postoperative variables:                                                
   ICU time \[days\]              4 (3--9)            4 (3--8)            4 (3--8)
   Mechanical ventilation \[h\]   18 (7--73)          22 (8--75)          12 (7--39)
   30-day mortality (%)           14.9                14.9                8.9

FR -- Fresenius crystalloid cardioplegic solution, ST -- St. Thomas crystalloid cardioplegic solution, BL -- Calafiore cold blood cardioplegic solution, CBP -- cardiopulmonary bypass time, Ao-x-clamp -- aortic cross-clamp time, ICU time -- intensive care unit stay time. Data presented as median and ranges.

This observational study has been approved by the local Ethics Committee (resolution: 75/12 from 05.01.2012).

Cardioprotection {#sec3.2}
----------------

Patients were divided into three groups according to cardioplegia type. Cold crystalloid St. Thomas cardioplegia (ST) was used from 03.01.2006 to 01.03.2008 and was administered to 440 patients. Cold crystalloid Fresenius cardioplegia (FR) was used from 02.03.2008 to 12.11.2011 and was received by 432 patients. Cold blood Calafiore cardioplegia (BL) use was initiated in our department on 25.08.2010 and was administered during 257 operations. The composition of each cardioplegic solution in given in [Table III](#t0003){ref-type="table"}. Throughout the whole study period all types of cardioplegic solutions were administered in the indirect (via the aortic root) or direct antegrade way.

###### 

Chemical composition of crystalloid component of cardioplegic solutions

  Component \[mM/dm^3^\]            ST       FR       BL
  --------------------------------- -------- -------- ------------
  K^+^                              16.37    5        670.74
  Cl^--^                            2.28     60.92    475.5
  Na^+^                             93.94    19.61    154
  Ca^+^                             16.66    0.97     --
  SO~4~^2--^                        1.21     --       --
  H~2~PO~4~^--^                     1.28     --       --
  Mannitol                          200.03   200.03   --
  Magnesium DL-hydrogen aspartate   --       1.6      57.71
  6-Methylprednisolone              --       0.67     --
  Sodium bicarbonate                25       25       --
  Gentamycin                        --       0.042    --
  pH                                4--6     5--7     7.35--7.45

FR -- Fresenius crystalloid cardioplegic solution, ST -- St. Thomas crystalloid cardioplegic solution, BL -- Calafiore cold blood cardioplegic solution.

Administration of cold crystalloid cardioplegia (at 4°C) to the coronary arteries was performed by an external, pneumatic system operated by the anesthesiologist. The solution was delivered under the pressure of no more than 150 mm Hg every 30 min. The first dose was 10 ml/kg patient's body weight, and the next doses were 5 ml/kg patient's body weight.

The administration of cold blood cardioplegia (4°C) to the coronary arteries was performed by an additional pump of the heart-lung machine with a heat exchanger operated by the perfusionist. Cardioplegia infusion was under the pressure of no more than 150 mm Hg every 30 min for 3 to 3.5 min.

Statistical methods {#sec3.3}
-------------------

Multivariable regression models were created to assess the co-influence of specific types of cardioplegia on selected clinical variables (with the binominal function or Poisson function). The dependent outcome variables were the following parameters:

-   30-day mortality -- "Death_30d",

-   the low cardiac output syndrome (defined as acidosis and oliguria occurrence accompanied by the necessity of inotropic drug support and vasodilatation drug administration) -- "LCOS",

-   delayed sternal closure -- "DSC",

-   mechanical ventilation time longer than the median value of the entire cohort (18 h) -- "INTUB_time",

-   intensive care unit stay longer than the median value for all patients (4 days) -- "ICU_LOS",

-   hospitalization time longer than the median value for all patients (12 days) -- "HOSP_time",

-   vasoactive-inotropic score value higher than the median value of all patients (4.7) -- "VIS" (vasoactive-inotropic score mcg/kg/min = DPA + DBX + 100 × ISO + 100 × ADR (where: DPA = dopamine, DBX = dobutamine, ISO = isoprenaline, ADR = adrenaline, score modified according to a local catecholamine administration policy) \[[@cit0007], [@cit0008]\]),

-   the total amount of complications (including: acute renal failure requiring hemodiafiltration, pneumonia, cardiac arrhythmia, bleeding requiring reoperation, neurological complications, metabolic acidosis, pulmonary hypertension crisis and mediastinitis) -- "Compl_count".

The aforementioned models were developed using the following explanatory variables:

-   type of cardioplegia -- blood cardioplegia (BL) vs. crystalloid cardioplegia (CR = St. Thomas cardioplegia + Fresenius cardioplegia) = "Cardiopl_double"; or blood cardioplegia vs. St. Thomas cardioplegia (ST) vs. Fresenius cardioplegia (FR) = "Cardiopl_triple"; both options were used interchangeably,

-   patient's sex -- "Sex",

-   patient's age (in days) -- "Age",

-   type of congenital cardiac disease "CHD" (following cardiac diseases were considered: "AS/AI" -- aortic valve diseases -- complex and simple; "ASDII" -- atrial septal defect, "VSD" -- ventricular septal defect, "AVSD" -- all types of atrioventricular septal defect (unbalanced forms were excluded), "ToF" -- tetralogy of Fallot, "AVVI" -- isolated atrioventricular valves diseases, "TGA" -- transposition of great arteries excluding single ventricle, "UVH" -- all spectrum of single ventricle heart, including hypoplastic left heart syndrome (HLHS), "MIX" -- other, less frequent cardiac malformations),

-   patient's body surface area (m^2^) -- "BSA",

-   presence of concomitant genetic diseases -- "Genetic" -- mainly Down's syndrome,

-   surgeon performing the operation -- "Surgeon",

-   redo surgery -- "REDO",

-   urgent surgery -- "Urgency",

-   total operation time (min) -- "OP_time",

-   cardiopulmonary bypass time (min) -- "CBP_time",

-   aortic cross-clamp time (min) -- "Ao-X-clamp_time",

-   use of deep hypothermic circulatory arrest -- "DHCA".

Continuous variables: BSA, Age, OP_time, CBP_time and Ao-X-clamp_time were discretized to quartiles in the majority of models.

Development of statistical models {#sec3.4}
---------------------------------

For each dependent outcome variable a nonlinear multivariable regression model was created (Poisson version for "Compl_count" variable, binominal logistic version for the rest of variables). All independent variables entered the preliminary model. A genetic algorithm was used to search for the best model \[[@cit0009]\] by application of the Akaike information criterion \[[@cit0010]\]. A genetic algorithm is one of the best alternatives to the strategy of fitting all possible models, which definitely makes the computational time prohibitive even for recent computers. Conversely, a genetic algorithm explores only a subset of all possible models, randomly but with the preponderance towards the best model. This is achieved by simulation of biological processes: generation of the model's offspring with a mutation, recombination with another model and finally model selection. This makes genetic algorithms computationally fast. The leave-one-out cross-validation (LOOCV) method was used to validate the best model by its comparison to the preliminary model using a cross-validation estimate of prediction error. The smaller estimate of prediction error in the developed model than in the preliminary one signified the better performance of the former. The impact of an independent variable on an outcome variable (associated with the regression coefficient) was described by the odds ratio (OR) with 95% confidence interval (CI). Thus, the lower and upper confidence limits yielded an interval estimate of OR at 0.05 α. Predicting variables were considered significant at *p* \< 0.05.

Statistical software {#sec3.5}
--------------------

The R Project (R: A Language and Environment for Statistical Computing, version 3.0.1) with the glmulti library implementing a genetic algorithm for the model search was used for statistical analysis \[[@cit0011]\]. Leave-one-out cross-validation was performed using a boot library \[[@cit0012]\]. Because of time-consuming calculations, R batch scripts were created for automatic execution.

Results {#sec4}
=======

The variable "Type of cardioplegia" entered into 3 out of 8 created models and with other explanatory variables had a statistically significant impact on the following dependent variables: vasoactive-inotropic score, low cardiac output syndrome presence, total amount of complications.

The model of vasoactive-inotropic score value in studied cohort was explained by the following predictors ([Table IV](#t0004){ref-type="table"}):

###### 

Model of vasoactive-inotropic score value. Model type: binomial

  Variable                 *P*-value   Odds ratio   95% CI   
  ------------------------ ----------- ------------ -------- ---------
  Intercept                0.0033      0.2435       0.0932   0.6149
  Cardioplegia: FR         0.0416      1.5198       1.0165   2.2765
  Cardioplegia: ST         0.0140      1.6503       1.1078   2.4648
  Age: 90--319 days        0.0537      0.5785       0.3300   1.0058
  Age: 319--860 days       0.6587      0.8406       0.3900   1.8262
  Age: 860--999 days       0.5105      1.4862       0.4652   4.9541
  CHD type: ASDII          0.4268      0.7333       0.3431   1.5910
  CHD type: AVSD           0.3386      1.4717       0.6686   3.2680
  CHD type: AVVI           0.0495      2.3700       1.0090   5.6761
  CHD type: MIX            0.1619      1.7387       0.8051   3.8086
  CHD type: TGA            0.8591      1.0910       0.4207   2.8950
  CHD type: ToF            \< 0.0001   6.0350       2.6233   14.3336
  CHD type: UVH            0.2662      1.6706       0.6804   4.1770
  CHD type: VSD            0.6426      0.8423       0.4094   1.7523
  BSA: 0.25--0.38 m^2^     0.8534      0.9514       0.5616   1.6192
  BSA: 0.38--0.54 m^2^     0.0041      0.3245       0.1493   0.6951
  BSA: 0.54--0.59 m^2^     0.0002      0.0986       0.0287   0.3228
  Genetic                  0.1002      1.5265       0.9235   2.5360
  Redo surgery             0.0320      1.7736       1.0564   3.0173
  CBP time: 54--86 min     \< 0.0001   4.6875       2.6491   8.5421
  CBP time: 86--110 min    \< 0.0001   7.1750       3.9919   13.2737
  CBP time: 110--126 min   \< 0.0001   13.0896      6.9434   25.4268

Cross-validation estimate of prediction error: preliminary model: 0.179, the best model: 0.157.

CHD -- type of congenital cardiac disease, CBP time -- cardiopulmonary bypass time, FR -- Fresenius crystalloid cardioplegic solution, ST -- St. Thomas crystalloid cardioplegic solution, BSA -- patient's body surface area, ASD II -- atrial septal defect, AVSD -- atrioventricular septal defect, AVVI -- isolated atrioventricular valve malformations, MIX -- other, less frequent cardiac malformations, TGA -- all spectrum of transposition of great arteries, ToF -- tetralogy of Fallot, UVH -- all spectrum of single ventricle disease, including HLHS, VSD -- ventricular septal defect, CI -- confidence interval.

-   Increasing risk for vasoactive-inotropic score value higher than the cohort median:

    -   Type of cardioplegia -- use of crystalloid Fresenius (*p* = 0.0416) and St. Thomas cardioplegia (*p* = 0.014),

    -   Atrioventricular valve defect (*p* = 0.0495), and tetralogy of Fallot presence (*p* \< 0.001),

    -   Reoperation (*p* = 0.032),

    -   Cardiopulmonary bypass time longer than first quartile for studied population (CBP_time: in the second quartile: *p* \< 0.001; CBP_time: in the third quartile: *p* \< 0.001; CBP_time: in the fourth quartile: *p* \< 0.001),

-   Decreasing risk for vasoactive-inotropic score value higher than the cohort median:

    -   Patient's body surface area greater than the median value (BSA in the third quartile: *p* = 0.0041; BSA in the fourth quartile: *p* = 0.0002),

The low cardiac output syndrome occurrence model was explained by the following predictors ([Table V](#t0005){ref-type="table"}):

###### 

Model of low cardiac output syndrome occurrence. Model type: binomial

  Variable                       *P*-value   Odds ratio   95% CI   
  ------------------------------ ----------- ------------ -------- ---------
  Intercept                      \< 0.0001   0.0015       0.0001   0.0118
  Cardioplegia: FR               0.0015      3.3730       1.6436   7.4629
  Cardioplegia: ST               \< 0.0001   5.0853       2.4728   11.3444
  Age: 90--319 days              0.1729      0.6369       0.3333   1.2250
  Age: 319--860 days             0.2640      0.6440       0.2958   1.3932
  Age: 860--999 days             0.0017      0.2023       0.0720   0.5339
  CHD type: ASDII                0.1209      4.0899       0.7822   31.8598
  CHD type: AVSD                 0.1684      3.1425       0.7327   22.1247
  CHD type: AVVI                 0.0421      6.1369       1.2219   46.9253
  CHD type: MIX                  0.0336      5.6853       1.3674   39.2556
  CHD type: TGA                  0.1144      0.2409       0.0462   1.8487
  CHD type: ToF                  0.1165      3.7052       0.8569   26.1832
  CHD type: UVH                  0.0532      5.2252       1.1440   37.9075
  CHD type: VSD                  0.1506      3.3172       0.7696   23.4585
  Redo surgery                   0.0172      2.3611       1.1520   4.7631
  Urgency                        0.0242      2.2657       1.1079   4.6131
  Operation time: 150--205 min   0.5381      0.7135       0.2461   2.1706
  Operation time: 205--265 min   0.0831      2.4927       0.9216   7.4218
  Operation time: 265--960 min   0.1600      2.2686       0.7442   7.4485
  CBP time: 54--86 min           0.0360      4.3529       1.2307   20.8097
  CBP time: 86--110 min          0.0348      4.6372       1.2494   23.1424
  CBP time: 110--126 min         0.0004      14.2120      3.6971   73.0373

Cross-validation estimate of prediction error: preliminary model: 0.09, the best model: 0.087.

CHD -- type of congenital cardiac disease, CBP time -- cardiopulmonary bypass time, FR -- Fresenius crystalloid cardioplegic solution, ST -- St. Thomas crystalloid cardioplegic solution, ASD II -- atrial septal defect, AVSD -- atrioventricular septal defect, AVVI -- isolated atrioventricular valve malformations, MIX -- other, less frequent cardiac malformations, TGA -- all spectrum of transposition of great arteries, ToF -- tetralogy of Fallot, UVH -- all spectrum of single ventricle disease, including HLHS, VSD -- ventricular septal defect, CI -- confidence interval.

-   Increasing risk for LCOS in studied population:

    -   Type of cardioplegia -- use of crystalloid Fresenius (*p* = 0.0015) and St. Thomas cardioplegia (*p* \< 0.001),

    -   Presence of atrioventricular valve defect (*p* = 0.0421) and other less frequent cardiac malformations (*p* = 0.0336),

    -   Reoperation (*p* = 0.0172),

    -   Urgent operation (*p* = 0.0242),

    -   Cardiopulmonary bypass time longer than first quartile of the cohort (CBP_time: second quartile: *p* = 0.036; CBP_time: third quartile: *p* = 0.0348; CBP_time in the fourth quartile: *p* \< 0.001),

-   Decreasing risk for LCOS appearance in studied population:

    -   Patient's age in 4^th^ quartile of the cohort (*p* = 0.0017).

The model of the total amount of complications was explained by the following predictors ([Table VI](#t0006){ref-type="table"}):

###### 

Model of total amount of complications. Model: Poisson

  Variable           *P*-value   Odds ratio   95% CI   
  ------------------ ----------- ------------ -------- --------
  Intercept          0.0902      0.4630       0.1791   1.0803
  Cardioplegia: FR   0.0555      1.2647       0.9984   1.6154
  Cardioplegia: ST   0.0002      1.5507       1.2338   1.9680
  CHD type: ASDII    0.9947      1.0027       0.4765   2.3668
  CHD type: AVSD     0.0099      2.6279       1.3431   5.9410
  CHD type: AVVI     0.0005      3.8997       1.9005   9.0694
  CHD type: MIX      0.0034      2.9466       1.5253   6.6075
  CHD type: TGA      0.9714      1.0139       0.5058   2.3294
  CHD type: ToF      0.0004      3.7040       1.9026   8.3398
  CHD type: UVH      0.0030      3.0527       1.5540   6.9189
  CHD type: VSD      0.0611      2.0139       1.0309   4.5478
  Redo surgery       \< 0.0001   1.6633       1.3156   2.0846
  Urgency            0.0126      1.3473       1.0652   1.7014
  Age                \< 0.0001   1.0011       1.0008   1.0014
  BSA                \< 0.0001   0.0011       0.0003   0.0043
  Operation time     \< 0.0001   1.0043       1.0034   1.0051
  CBP time           0.0324      1.0002       1.0000   1.0003

Cross-validation estimate of prediction errors: preliminary model: 2.01, the best model: 1.96.

CHD -- type of congenital cardiac disease, CBP time -- cardiopulmonary bypass time, FR -- Fresenius crystalloid cardioplegic solution, ST -- St. Thomas crystalloid cardioplegic solution, BSA -- patient's body surface area, ASD II -- atrial septal defect, AVSD -- atrioventricular septal defect, AVVI -- isolated atrioventricular valve malformations, MIX -- other, less frequent cardiac malformations, TGA -- all spectrum of transposition of great arteries, ToF -- tetralogy of Fallot, UVH -- all spectrum of single ventricle disease, including HLHS, VSD -- ventricular septal defect, CI -- confidence interval.

-   Increasing the amount of complications:

    -   Type of cardioplegia -- use of crystalloid St. Thomas cardioplegia (*p* = 0.0002),

    -   Complex cardiac malformations presence (AVSD: *p* = 0.0099; AVVI: *p* \< 0.001; MIX: *p* = 0.0034; ToF: *p* \< 0.001; UVH: *p* = 0.003),

    -   Reoperation (*p* \< 0.001),

    -   Urgent operation (*p* = 0.0126),

    -   Operation time, cardiopulmonary bypass time and patient's age -- odds ratios not exceeding more than 1.0011 (OR and CI -- [Table V](#t0005){ref-type="table"}),

-   Decreasing the total amount of complications:

    -   Patient's body surface (*p* \< 0.001).

The variable "Type of cardioplegia" entered into another two models explaining 30-day mortality and hospitalization time. However, the impact of used cardioplegia type was not statistically significant for these models ([Tables VII](#t0007){ref-type="table"} and [VIII](#t0008){ref-type="table"}).

###### 

Model of 30-day mortality. Model: binomial

  Variable                 *P*-value   Odds ratio   95% CI   
  ------------------------ ----------- ------------ -------- ---------
  Intercept                \< 0.0001   0.0114       0.0023   0.0432
  Cardioplegia: CR         0.1920      1.4502       0.8443   2.5917
  CHD type: ASDII          0.3584      0.5035       0.1097   2.2077
  CHD type: AVSD           0.2404      1.9116       0.6924   6.2581
  CHD type: AVVI           0.7547      1.2537       0.2934   5.3051
  CHD type: MIX            0.5689      1.3914       0.4716   4.7490
  CHD type: TGA            0.0039      0.1542       0.0446   0.5864
  CHD type: ToF            0.7357      1.2201       0.4026   4.2233
  CHD type: UVH            0.0231      4.0588       1.2741   14.7541
  CHD type: VSD            0.9720      0.9795       0.3233   3.3931
  Urgency                  \< 0.0001   5.4288       3.0082   9.8320
  CBP time: 54--86 min     0.2592      2.0555       0.6322   8.1218
  CBP time: 86--110 min    0.0681      3.1152       1.0011   12.0565
  CBP time: 110--126 min   \< 0.0001   13.5062      4.5520   50.8774
  DHCA                     0.7079      1.1532       0.5405   2.4160

Cross-validation estimate of prediction errors: preliminary model: 0.093, the best model: 0.082.

CHD -- type of congenital cardiac disease, CBP time -- cardiopulmonary bypass time, DHCA -- use of deep hypothermic circulatory arrest, CR -- crystalloid cardioplegia, ASD II -- atrial septal defect, AVSD -- atrioventricular septal defect, AVVI -- isolated atrioventricular valve malformations, MIX -- other, less frequent cardiac malformations, TGA -- all spectrum of transposition of great arteries, ToF -- tetralogy of Fallot, UVH -- all spectrum of single ventricle disease, including HLHS, VSD -- ventricular septal defect, CI -- confidence interval.

###### 

Model of hospitalization time. Model: binomial continuous

  Variable           *P*-value   Odds ratio   95% CI   
  ------------------ ----------- ------------ -------- --------
  Intercept          0.7933      0.9292       0.5364   1.6130
  Cardioplegia: CR   0.1194      0.7892       0.5856   1.0633
  CHD type: ASDII    0.0001      0.3252       0.1879   0.5594
  CHD type: AVSD     0.0011      0.3468       0.1825   0.6503
  CHD type: AVVI     0.7515      0.8865       0.4206   1.8787
  CHD type: MIX      0.0262      0.4906       0.2604   0.9160
  CHD type: TGA      0.2248      0.6002       0.2621   1.3662
  CHD type: ToF      0.8247      1.0695       0.5891   1.9398
  CHD type: UVH      0.1486      0.5763       0.2708   1.2131
  CHD type: VSD      0.1346      0.6728       0.3989   1.1289
  Genetic            0.0004      2.1924       1.4221   3.4082
  Urgency            0.0595      1.5593       0.9849   2.4866
  Ao_X\_clamp time   0.0006      1.0099       1.0043   1.0157
  DHCA               0.1262      0.9773       0.9473   1.0052

Cross-validation estimate of prediction errors: preliminary model: 0.272, the best model: 0.229.

CHD -- type of congenital cardiac disease, Ao_X\_clamp time -- aortic cross-clamp time, DHCA -- use of deep hypothermic circulatory arrest, CR -- crystalloid cardioplegia, ASD II -- atrial septal defect, AVSD -- atrioventricular septal defect, AVVI -- isolated atrioventricular valve malformations, MIX -- other, less frequent cardiac malformations, TGA -- all spectrum of transposition of great arteries, ToF -- tetralogy of Fallot, UVH -- all spectrum of single ventricle disease, including HLHS, VSD -- ventricular septal defect, CI -- confidence interval.

Models of delayed sternal closure, mechanical ventilation time and intensive care unit stay time were created. However, the variable "Type of cardioplegia" did not enter into the mentioned models.

Discussion {#sec5}
==========

This study shows that the type of cardioplegic solution, as well as the method of its administration, has a significant co-influence on selected postoperative clinical parameters such as vasoactive-inotropic score, low cardiac output syndrome presence and total amount of complications. These variables reflect postcardiotomy heart failure in children after CHD correction in a complementary way. The impact of cardioplegia type on these parameters described as the odds ratio ranges between 1.44 and 5.09 and is never dominant in relation to other explanatory variables in specific models. This indicates the presence of more influential factors playing roles in aforementioned models as seen in a clinical context. However, cardioplegia type together with negative composition of other clinical variables (prolonged cardiopulmonary bypass time, low patient's body surface area, urgency of operation and complex CHD) can have a significant impact on postoperative course. In contrast to blood cardioplegia, crystalloid cardioplegic solutions have a significantly negative influence on postoperative course in presented regression models. This may suggest a similar, if not better, clinical result of cold blood cardioplegia administration. This observation corresponds with other reports \[[@cit0013], [@cit0014]\]. Similarly, the influence of cardioplegia type was not dominant relatively to other clinical variables examined in this study.

Contrary to our findings, Young *et al.* \[[@cit0015]\] described less frequent inotropic drug administration in patients who received crystalloid cardioplegia. Similarly, Sinha *et al.* \[[@cit0016]\] reported shorter mechanical ventilation time and shorter hospital stay time in patients receiving crystalloid cardioplegia.

The cardioplegia type variable entered into the model of 30-day mortality, but without statistical significance. This observation is similar to other studies where type of used cardioplegia did not impact in-hospital mortality \[[@cit0013], [@cit0015]\].

Cardioplegia type was not a predictor in mechanical ventilation time and intensive care unit stay time models. It can be explained by a stronger influence of other non-cardiac variables. They may affect the long ICU stay time due to prolonged mechanical ventilation (e.g. caused by pulmonary hypertension or pneumonia). It corresponds with other observations \[[@cit0017], [@cit0018]\] where type of cardioprotection has no influence on respiratory time, ICU stay time or hospitalization time. Similarly, the presence of delayed sternal closure (DSC) was not related to the type of used cardioplegia. It is comparable to other reports where the following variables may have a prevalent influence on DSC usage: cardiopulmonary bypass time, aortic cross clamp time, postoperative massive bleeding, severe preoperative patient's condition \[[@cit0019]--[@cit0021]\].

This study has several limitations. It is a retrospective observational study concerning a 6-year period. Intraoperative and postoperative procedures, quality of ICU care and surgeons' technique have evolved during that time. It could have affected the results of statistical analyses. The analysis of surgeon's influence on the studied variables showing a lack of impact may mitigate the bias connected with the operator's learning curve and the era of operation.

A certain drawback of the study may be connected with the multiplicity -- creation of different models of clinical outcome based on the same set of independent variables. However, from the data-mining perspective this study tried to verify whether there is any influence of the most interesting variable -- cardioplegia type -- on our dependent variables that were not completely isolated one from another and were different manifestations of potentially inadequate cardioprotection.

The next limitation is the absence of a myocardial injury biomarker, whose postoperative blood levels could be correlated with type of used cardioplegia. These markers were not examined due to the retrospective character of the study. Moreover, myocardial injury biomarker release after operations with cardiopulmonary bypass and heart arrest makes their routine use difficult and confined to selected cases only \[[@cit0022], [@cit0023]\].

Better postoperative myocardial contractility was reported after blood cardioplegia administration \[[@cit0024], [@cit0025]\]. Due to the incompleteness of echocardiographic data this parameter was not included in the study.

Conclusions {#sec6}
===========

Cardioprotection together with other factors influences postoperative clinical results in children with CHD. Contrary to crystalloid cardioplegia, blood cardioplegia does not adversely affect the outcome. Moreover, its application may have a protective effect by decreasing low cardiac output incidence and related complications.
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